Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1222 phase III COVID-19 prevention study in adults
2020-005226-28Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing AZD1222 with Placebo (2 arms). Primary endpoint: First RT-PCR-positive symptomatic COVID-19 case after full vaccination. Started Nov 2020; status: completed.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005226-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005226-28.